Skip to main content
Clinical Trials/NCT01769612
NCT01769612CompletedNot Applicable

Evaluation of a Diagnostic Device, CL Detect Rapid Test, for the Diagnosis of Cutaneous Leishmaniasis in Tunisia

U.S. Army Medical Research and Development Command2 sites in 1 country168 target enrollmentStarted: January 2013Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
168
Locations
2
Primary Endpoint
Positive Result Comparison: CL Detect Rapid Test With Microscopy and Culture Results

Study Overview

Brief Summary

The purpose of the study is to evaluate the sensitivity and specificity of CL Detect, in subjects with suspected CL in Tunisia.

Detailed Description

Subjects were selected based on clinical appearance of the skin lesion characteristics of cutaneous leishmaniasis (CL). Study compared the CL Detect Rapid Test vs microscopic identification of Leishmania amastigotes in a stained lesion sample. Two diagnostic samples were collected from the subjects lesion in the following order: 1) obtained with a dental broach for use with the CL Detect Rapid Test and 2) a second sample was obtained by scraping for use in the microscopic identification of amastigotes. Samples were analyzed by microscopy and CL Detect Repaid Test by different operators who evaluated each sample independently blinded to the other assay result.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • At least 18 years of age and generally healthy
  • Subject able to give written informed consent
  • Subject has a lesion suspicious for leishmaniasis that satisfies the following criteria for an index lesion:
  • less than 4 months in age
  • primarily ulcerative, ie not purely verrucous or nodular, and does not have clear clinical evidence of cellulitis
  • in a location suitable for collecting samples by dental broach, scraping, and aspiration
  • In the opinion of the investigator, the subject is capable of understanding and complying with the protocol

Exclusion Criteria

  • Received treatment for leishmaniasis within the last 2 months prior to signing consent, with the exception of mercurochrome

Outcomes

Primary Outcomes

Positive Result Comparison: CL Detect Rapid Test With Microscopy and Culture Results

Time Frame: within 1 hour after taking samples

Comparison of CL Detect Rapid Test positive results with Microscopy and Culture results. Note: only data where results for all three methods were available were included in the analysis.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
U.S. Army Medical Research and Development Command
Sponsor Class
Fed
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials